Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

The Liver Imaging Reporting and Data System (LI-RADS) is composed of four individual
algorithms intended to standardize the lexicon, as well as reporting and care, in patients with …

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Primary liver tumours (ie hepatocellular carcinoma (HCC) or intrahepatic
cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the
sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Image-guided tumor ablation has become a well-established hallmark of local cancer
therapy. The breadth of options available in this growing field increases the need for …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma …

Transarterial chemoembolization (TACE) is the standard of care for patients with
intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of …

Hepatocellular carcinoma is a common malignancy for which prevention, screening,
diagnosis, treatment, and surveillance demand a multidisciplinary approach. Knowledge of …